Immutep has outlined a new development path for eftilagimod alfa after its investigation into the failed Phase III TACTI-004 lung cancer study identified structural differences between drug manufactured at two production scales. The company said subtle analytical differences, including an N-glycan variation, were found between efti produced at the 2,000-liter scale used exclusively in TACTI-004 and material previously produced at 200 liters for several earlier successful clinical studies. Immutep has now contracted another 200-liter manufacturing run and intends to concentrate future registration-directed development on PD-L1-negative head and neck squamous cell carcinoma and neoadjuvant soft tissue sarcoma.
The update offers a possible explanation for one of the most damaging clinical setbacks in Immutep’s recent history, but it does not yet establish that manufacturing differences caused TACTI-004 to fail. The root-cause investigation remains ongoing, and the company has described the structural variations as potentially relevant because patients in the Phase III trial showed a markedly different immune activation profile from participants in earlier efti studies. That distinction is critical as Immutep attempts to determine whether TACTI-004 represented a trial-specific problem or exposed a broader uncertainty surrounding efti’s clinical activity.
Manufacturing-scale differences emerge as Immutep investigates the unexpected TACTI-004 failure
TACTI-004 was evaluating efti with Merck & Company’s Keytruda and chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer. Immutep discontinued the randomized Phase III study in March after an independent data monitoring committee recommended stopping the program for futility during a prespecified interim analysis. Subsequent analysis showed an objective response rate of 42.9% in the efti combination arm compared with 55.1% for patients receiving Keytruda and chemotherapy with placebo, an unexpected result given the signals observed in earlier studies.
That discrepancy prompted Immutep to examine clinical, operational, pharmacological and manufacturing factors. The company now says the available evidence does not point toward trial-protocol problems, meaningful baseline imbalances, safety findings, randomization issues or broader clinical-trial execution failures as an explanation for the result. Instead, analytical work has identified structural differences between batches produced at different manufacturing scales.
Earlier clinical development relied on efti manufactured at 200-liter scale. Immutep said 10 good manufacturing practice batches produced at that scale were used in studies including TACTI-mel, TACTI-002 and INSIGHT-003, while TACTI-004 used material produced exclusively at 2,000-liter scale. The company specifically pointed to a subtle difference in N-glycan structure among the findings now being examined.
Glycosylation can influence the structure and biological behavior of protein-based medicines, making such a finding scientifically relevant. However, the presence of a structural difference does not demonstrate that it altered clinical efficacy, and Immutep has not yet established a direct causal link between the manufacturing change and the Phase III result. The final root-cause analysis will therefore be important before the TACTI-004 outcome can reasonably be attributed primarily to product-manufacturing variability.
The biological observations nevertheless give Immutep a reason to investigate the hypothesis further. Preliminary immune-monitoring data disclosed in July showed that TACTI-004 participants receiving efti exhibited a substantially different immune activation profile from patients across earlier studies, including nearly 600 patients assessed across five prior trials. Those findings already suggested that something about TACTI-004 differed from the experience generated across the broader efti program.
Head and neck cancer becomes a priority after encouraging survival in PD-L1-negative patients
Rather than returning immediately to first-line lung cancer, Immutep plans to narrow its registration-focused strategy to indications where it believes the existing evidence and regulatory path are stronger. One priority is first-line head and neck squamous cell carcinoma in patients whose tumors have a PD-L1 Combined Positive Score below one.
That population represents an important unmet need because PD-L1-negative patients have fewer chemotherapy-free immunotherapy options. In the Phase IIb TACTI-003 program, efti combined with Keytruda produced median overall survival of 17.6 months among 31 evaluable patients with CPS below one. Immutep compared that result with historical median survival figures of 10.7 months for cetuximab plus chemotherapy and 11.3 months for anti-PD-1 therapy with chemotherapy, although comparisons across separate trials cannot establish superiority.
The United States Food and Drug Administration has granted Fast Track designation to efti in first-line head and neck cancer, and Immutep said its previous discussions with the agency have been constructive. The company now appears to view this narrower biomarker-defined population as a potentially faster and less risky registration opportunity than returning immediately to a broad late-stage lung cancer program.
This strategy also illustrates how the TACTI-004 setback has changed efti’s development trajectory. Before March, first-line non-small cell lung cancer represented the most advanced and commercially expansive opportunity for the program. The revised approach places greater emphasis on smaller settings where earlier data are more differentiated and where the clinical unmet need may allow a clearer regulatory argument.
Soft tissue sarcoma offers a second registration route supported by positive Phase II pathology data
Immutep’s other priority is neoadjuvant treatment of resectable soft tissue sarcoma. The investigator-led EFTISARC-NEO Phase II study evaluated efti with radiotherapy and Keytruda before surgery and met its primary endpoint, producing median tumor hyalinization or fibrosis of 51.5% among 38 evaluable patients. The result significantly exceeded the prespecified 35% threshold and historical levels of approximately 15% associated with radiotherapy alone.
Tumor hyalinization and fibrosis provide a pathological indication of treatment effect and have been associated with subsequent outcomes in soft tissue sarcoma, although mature disease-free and overall survival data remain important for understanding the longer-term clinical significance. Translational analyses also showed increases in inflammatory cytokines and chemokines consistent with efti’s proposed immune-activating mechanism.
The FDA granted efti Orphan Drug Designation in soft tissue sarcoma in April 2026. The designation can provide development incentives and, if approval is eventually obtained, potential United States market exclusivity for the orphan indication. Immutep now appears to view the combination of positive Phase II pathology results, regulatory designation and relatively concentrated patient population as a practical route for rebuilding confidence in the program.
The company is targeting the second half of 2027 for initiation of its next clinical studies, although that schedule remains dependent on final protocol decisions, regulatory discussions, manufacturing work, partnering and available resources. The gap before new trials begin means efti is unlikely to generate a rapid late-stage clinical catalyst, making manufacturing validation and regulatory clarity particularly important over the coming year.
Returning to 200-liter manufacturing may reduce uncertainty but creates new development questions
Immutep has contracted a fresh 200-liter efti manufacturing campaign based on its current root-cause findings. Returning to the scale used across earlier positive Phase I and Phase II studies provides a logical way to remove one variable before future clinical development resumes.
The decision also creates questions around eventual commercial manufacturing. A therapy intended for regulatory approval ultimately needs a scalable, reproducible manufacturing process capable of supporting larger trials and commercial demand. If clinical activity differs meaningfully depending on manufacturing scale, Immutep will need to establish why that difference occurs and demonstrate that the selected process consistently produces material with the intended biological characteristics.
That issue could become as important as clinical trial design. Regulators routinely scrutinize comparability when biologic manufacturing processes change, particularly where structural attributes may influence potency or immune activity. Immutep’s ability to characterize the differences between the 200-liter and 2,000-liter material and establish reliable product specifications will therefore be central to any future registration program.
Dr. Reddy’s Laboratories, which licensed efti rights across certain territories in January, remains supportive of the revised approach and is participating in discussions around development. Immutep retains rights across major markets including North America, Europe and Japan as well as global manufacturing responsibilities, while remaining eligible for as much as $349.5 million in potential milestones from the Dr. Reddy’s agreement plus royalties.
Immutep shares rise as investors cautiously respond to a possible explanation for the Phase III setback
The market initially responded positively to the September 11 update in Australia. Immutep shares closed approximately 5.7% higher at A$0.05, adding roughly A$3.5 million in market value, suggesting investors viewed the manufacturing findings and clearer development priorities as modestly constructive.
That reaction needs to be placed against the much larger loss in value following the TACTI-004 failure. Immutep’s United States-listed American depositary receipts closed at approximately $0.325 on September 10 after declining 8.5% during that session, while the company’s Nasdaq market capitalization was approximately $47 million. The shares remain far below levels seen before the Phase III setback, demonstrating that investors continue to assign substantial risk to the efti program.
Immutep ended June with A$68.87 million in cash, cash equivalents and term deposits and has introduced cost reductions following discontinuation of TACTI-004. Management expects the current runway to extend well into the first half of 2028, potentially providing enough time to complete the manufacturing work and begin the next studies without immediate financing pressure.
The September 11 update improves the outlook primarily by giving Immutep a plausible path forward rather than resolving the uncertainty created by TACTI-004. A manufacturing-related explanation would be considerably more favorable to efti’s broader development prospects than evidence that its underlying immune mechanism failed in a large randomized study, but that hypothesis still requires validation.
The next phase will therefore depend on whether further analytical work confirms a meaningful relationship between manufacturing scale and biological activity, whether regulators agree with Immutep’s proposed registration strategies and whether new 200-liter material behaves consistently with earlier clinical batches. Only then will the company be in a stronger position to determine whether TACTI-004 represented an isolated manufacturing problem or a more fundamental challenge for efti.
